WBB Securities Downgrades PharmAthene (PIP) to Speculative Buy
PIP Hot Sheet
Rating Summary:0 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
WBB Securities downgrades PharmAthene (NYSE: PIP) from Strong Buy to Speculative Buy. Price target cut from $6.50 to $3.50.
To see all the upgrades/downgrades on shares of PIP, visit our Analyst Ratings page.
PharmAthene, Inc., a biodefense company, together with its subsidiaries, engages in development and commercialization of medical countermeasures against biological and chemical weapons in the United States.
To see all the upgrades/downgrades on shares of PIP, visit our Analyst Ratings page.
PharmAthene, Inc., a biodefense company, together with its subsidiaries, engages in development and commercialization of medical countermeasures against biological and chemical weapons in the United States.
You May Also Be Interested In
- UPDATE: UBS Downgrades Wisconsin Energy (WEC) to Neutral; Taking Some Off The Table
- Brean Murray Carret & Co. Downgrades NetApp (NTAP) to Hold; Visibility Challenged
- Needham & Company Reiterates a 'Buy' on UQM Technologies (UQM); Increasing EV Adoption
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
